^
Association details:
| Biomarker: | ER positive |
|---|---|
| Cancer: | Estrogen Receptor Positive Breast Cancer |
| Drug: | Ibrance (palbociclib) (CDK4 inhibitor, CDK6 inhibitor) + zemirciclib (AZD4573) (CDK9 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Targeting transcriptional regulation with a CDK9 inhibitor suppresses growth of endocrine- and palbociclib-resistant ER+ breast cancers
Published date:
10/06/2023
Excerpt:
The CDK9 inhibitor, AZD4573, currently in clinical trials for hematological malignancies, acted synergistically with palbociclib in these ER+ in vitro 2D and 3D models. Additionally, in two independent endocrine- and palbociclib-resistance patient-derived xenografts, treatment with AZD4573 in combination with palbociclib and fulvestrant resulted in tumor regression.
DOI:
https://doi.org/10.1158/0008-5472.CAN-23-0650
